Faatz, H.
Feltgen, N.
Gutfleisch, M.
Heimes-Bussmann, B.
Krohne, T. U.
Liakopoulos, S.
Liegl, R.
Lommatzsch, A.
Mussinghoff, P.
Rehak, M.
Schmitz-Valckenberg, S.
Spital, G.
Stanzel, B.
Ziemssen, F.
Hägele, B.
Junkes, C.
Porstner, M.
Vögeler, J.
Gmeiner, B.
Pauleikhoff, D. http://orcid.org/0000-0003-3691-291X
Funding for this research was provided by:
Novartis Pharma
Article History
Received: 4 May 2022
Revised: 27 July 2022
Accepted: 25 August 2022
First Online: 20 September 2022
Einhaltung ethischer Richtlinien
:
: <i>H. Faatz</i>: Novartis (C, S); Heidelberg Engineering (S). N. <i>Feltgen</i>: Alimera Sciences (C, S), Novartis (C, S), Roche (C, S); Allergan (S), Bayer (S), Heidelberg Engineering (S). <i>M. Gutfleisch</i>: Novartis (F), Bayer (F, R). <i>B. Heimes-Bussmann</i>: Bayer (B). <i>T.U. Krohne</i>: Alimera Sciences (R, C), Allergan (R), Bayer (F, R, C), Heidelberg Engineering (R), Novartis (F, R, C), Roche (R, C). <i>S. Liakopoulos</i>: Consultant: Allergan (C, S), Apellis (C, S), Bayer (C, S), Novartis (C, S), Alcon (S), Heidelberg Engineering (S), Zeiss (S). <i>R. Liegl</i>: Novartis, DORC. <i>A. Lommatzsch</i>: Allergan (R, C), Bayer (R, C), Heidelberg Engineering (R), Novartis (F, R, C), Roche (R). <i>P. Mussinghoff</i>: F: Novartis Pharma GmbH, BMBF; R: OD-OS GmbH. <i>D. Pauleikhoff</i>: Bayer (F, R, C), Heidelberg Engineering (R), Novartis (F, R, C), Roche (R, C). <i>M. Rehak</i>: Alimera Sciences (R, C), Allergan (R, C), Bayer (R, C), Heidelberg Engineering (R), Novartis (F, R, C), Roche (R). <i>S. Schmitz-Valckenberg</i>: Acucela (F), AlphaRET (F), Bioeq/Formycon (F), Carl Zeiss Meditec (F), Heidelberg Engineering (F, R), Katairo, Novartis (F, C), Pixium (C), Roche (F, C), SparingVision. Apellis (C, R). <i>G. Spital</i>: Bayer (R, C), Novartis (F, R, C) Roche (C), Allergan (R). <i>B. Stanzel</i>: Alimera Sciences (R, C), Allergan (R), Bayer (R), Carl Zeiss Meditec (F), Geuder AG (F, R, C, P) Heidelberg Engineering (F), Iridex (R), Meridian Medical (F, C), Novartis (R, C), Roche (R, C), Vitreq (F). F. Ziemssen: Alimera Sciences (C, S), Allergan/AbbVie (C, S), Bayer (C, S, F), Boehringer-Ingelheim (C), Novartis (C, S, F), Novo Nordisk (C), MSD (C), Oxurion (C), Roche/Genentech (C, S, F), BDI (S), CME Health (S), ODOS (S), BMBF (F), Clearside (F), DFG (F), Kodiak (F), Iveric (F), Ophtea (F), Regeneron (F). <i>B. Hägele, C. Junkes, M. Porstner, J. Vögeler, B. Gmeiner</i>: full time employment at Novartis Pharma GmbH. <i>B. Gmeiner</i>: shareholder of Novartis Pharma AG. (Disclosure codes: F, financial support of research projects; R, recipient of lecture fees, travel reimbursements; C, consultant; P, Patent.)
: Für diesen Beitrag wurden von den Autor/-innen keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.